Compensation for cures: Why we should pay a premium for participation in ‘challenge studies’
Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments - including risky experimental treatments such as phage therapy and vaccines - is an important part of improving our ability to treat infectio...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
[2019]
|
| In: |
Bioethics
Year: 2019, Volume: 33, Issue: 7, Pages: 792-797 |
| IxTheo Classification: | NCH Medical ethics NCJ Ethics of science |
| Further subjects: | B
challenge studies
B antibiotic resistance B Consent B phage therapy B antibiotics |
| Online Access: |
Presumably Free Access Volltext (Verlag) Volltext (doi) |
| Summary: | Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments - including risky experimental treatments such as phage therapy and vaccines - is an important part of improving our ability to treat infectious diseases. In order to aid this research, we will argue that we should permit researchers to pay people any amount of money to compensate for the risks of participating in clinical trials, including ‘challenge studies’ that involve deliberately infecting patients. We think that standard worries about paying for participation in risky research are reducible to concerns that can be addressed with the right screening mechanisms. |
|---|---|
| ISSN: | 1467-8519 |
| Contains: | Enthalten in: Bioethics
|
| Persistent identifiers: | DOI: 10.1111/bioe.12596 |